ArticleMethods in molecular biology (Clifton, N.J.)2022
Computational Optics for Point-of-Care Breast Cancer Profiling.
Jouha Min, Matthew Allen, Cesar M Castro, Hakho Lee, Ralph Weissleder, Hyungsoon Im
Abstract read
In one paragraphArticle in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
6 authors.
Jouha MinCenter for Systems Biology, Massachusetts General Hospital, Boston, MA, USA.
Matthew AllenCenter for Systems Biology, Massachusetts General Hospital, Boston, MA, USA.
Cesar M CastroCenter for Systems Biology, Massachusetts General Hospital, Boston, MA, USA.
Hakho LeeCenter for Systems Biology, Massachusetts General Hospital, Boston, MA, USA.
Ralph WeisslederCenter for Systems Biology, Massachusetts General Hospital, Boston, MA, USA.
Hyungsoon ImCenter for Systems Biology, Massachusetts General Hospital, Boston, MA, USA. im.hyungsoon@mgh.harvard.edu.
Funding
Training Grant in Molecular Imaging Research (MGH/HMS)T32CA079443 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2000 to 2025
$10.1MEarly Detection through Novel OCEAN Technology - Ovarian Cancer Exosomal Analysis with NanoplasmonicsU01CA233360 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CASTRO, CESAR M, DINULESCU, DANIELA M · 2018 to 2022
$3.5MFAST-FNA immune cell profiling in HNSCCR01CA257623 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FAQUIN, WILLIAM CLAY, WEISSLEDER, MD, PHD, RALPH · 2021 to 2025
$3.3MClinical platform for high-throughput analyses of extracellular vesiclesR01CA229777 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI LEE, HAKHO, SKOG, JOHAN · 2018 to 2022
$3.2MSmartphone for molecular cancer diagnostic in AfricaUH3CA202637 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHABNER, BRUCE ALLAN, WEISSLEDER, MD, PHD, RALPH · 2018 to 2020
$2.9MAnalysis of scant cancer cells in fine needle aspiratesR33CA202064 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2016 to 2018
$1.3MNovel Nano-Plasmonic Technology for Quantitative Analysis of Cancer ExosomesR00CA201248 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI IM, HYUNGSOON · 2017 to 2019
$968kSingle Circulating Vesicle Analysis for Early Cancer DetectionR21CA236561 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2019 to 2021
$585kNano-plasmonic technology for high-throughput single exosome analysesR21CA217662 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI IM, HYUNGSOON · 2019 to 2021
$585kNovel nano-plasmonic technology for quantitative analysis of cancer exosomesK99CA201248 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI IM, HYUNGSOON · 2015 to 2016
$329kNCI NIH HHS K99 CA201248NCI NIH HHS R00 CA201248NCI NIH HHS R01 CA229777NCI NIH HHS R01 CA257623NCI NIH HHS R21 CA217662NCI NIH HHS R21 CA236561NCI NIH HHS R33 CA202064NCI NIH HHS T32 CA079443NCI NIH HHS U01 CA233360NCI NIH HHS UH3 CA202637
6 · The paper itselfAbstract
With the global burden of cancer on the rise, it is critical to developing new modalities that could detect cancer and guide targeted treatments in fast and inexpensive ways. The need for such technologies is vital, especially in underserved regions where severe diagnostic bottlenecks exist. Recently, we developed a low-cost digital diagnostic system for breast cancer using fine-needle aspirates (FNAs). Named, AIDA (artificial intelligence diffraction analysis), the system combines lens-free digital diffraction imaging with deep-learning algorithms to achieve automated, rapid, and high-throughput cellular analyses for breast cancer diagnosis of FNA and subtype classification for better-guided treatments (Min et al. ACS Nano 12:9081-9090, 2018). Although primarily validated for breast cancer and lymphoma (Min et al. ACS Nano 12:9081-9090, 2018; Im et al. Nat Biomed Eng 2:666-674, 2018), the system could be easily adapted to diagnosing other prevalent cancers and thus find widespread use for global health.
Indexed as
Breast NeoplasmsAlgorithmsArtificial IntelligenceFemaleHumansHyperplasiaPoint-of-Care SystemsArtificial intelligenceBreast cancerCellular analysisDeep-learning algorithmsGlobal healthPoint-of-care diagnostics
Identifiers
PMID34837178
PMCPMC9283060
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390